Investor Presentaiton
Investor presentation
Full year 2018
Slide 35
Region Latin America at a glance
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Million
80
Population with diabetes
Diabetes growth rate
NN Insulin MS
NN OAD MS
bDKK
16
NN GLP-1 MS
Full year 2018
Sales
(mDKK)
Growth²
120%
74%
Long-acting insulin³
708
13%
100%
Premix insulin4
122
8%
60-
95%
40
68
12
Fast-acting insulin5
351
38%
GLP-1
10.8%¹
80%
Human insulin
695
(4%)
Insulin
8
6.9%¹
60%
Total insulin
1,876
13%
39
GLP-16
544
27%
+ 40%
20
20
20
Other diabetes care?
66
37%
6.3%¹
OAD
20%
Diabetes care
2,486
16%
Obesity (SaxendaⓇ)
410
73%
0
2000
2017
2045
Nov
2013
0%
Nov
2018
Biopharm³
1,114
54%
Total
4,009
29%
Latin America population 2018: ~0.6 billion people and diabetes
prevalence ~9.3%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for last 5-year period
Competitor value market share comparison for insulin as of Nov 2018:
Novo Nordisk 46%, Sanofi 31% and Eli Lilly 19%
Competitor value market share comparison for GLP-1 as of Nov 2018:
Novo Nordisk 68%, Eli Lilly 31% and AstraZeneca 1%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Nov, 2018 value figures
2 Percentage change in local currency from full year 2017 to full year
2018
3 Comprises Tresiba®, XultophyⓇ and LevemirⓇ; 4 Comprises NovoMix®
and RyzodegⓇ; 5 Comprises NovoRapidⓇ; 6 Comprises VictozaⓇ;
7 Comprises Novo NormⓇ and needles; 8 Comprises primarily
NovoSeven®, NovoEight® and Norditropin®View entire presentation